gabapentin has been researched along with Adenocarcinoma, Basal Cell in 4 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 7.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| "We report a case of neutropenia occurring in a patient receiving gabapentin for neuropathic pain." | 3.72 | Neutropenia occurring after starting gabapentin for neuropathic pain. ( Derbyshire, E; Martin, D, 2004) |
| " Male Wistar rats fed with 2% gabapentin (1-(aminomethyl)cyclohexane acetic acid) in diet for 2 years developed pancreatic exocrine adenomas and adenocarcinomas." | 3.69 | Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin. ( de la Iglesia, FA; Fowler, ML; Lalwani, ND; Reddy, JK; Sigler, RE, 1995) |
| "Gabapentin, which has been suggested as an adjuvant analgesic for neuropathic pain introduced orally, rapidly and significantly alleviated his pain and we could subsequently dispense with ketamine and mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleming, GF | 1 |
| Derbyshire, E | 1 |
| Martin, D | 1 |
| Okada, M | 1 |
| Shinjo, T | 1 |
| Fowler, ML | 1 |
| Sigler, RE | 1 |
| de la Iglesia, FA | 1 |
| Reddy, JK | 1 |
| Lalwani, ND | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gabapentin and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials | 2015 |
3 other studies available for gabapentin and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Neutropenia occurring after starting gabapentin for neuropathic pain.
Topics: Adenocarcinoma; Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gab | 2004 |
[Gabapentin mitigates neuropathic pain in cancer patients--a case report].
Topics: Adenocarcinoma; Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2007 |
Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin.
Topics: Acetates; Adenocarcinoma; Adenoma; Amines; Animals; Base Sequence; Codon; Cyclohexanecarboxylic Acid | 1995 |